Monday, October 01, 2007

Supreme Court won't review CAFC ruling on Lilly's Zyprexa

Gannett News stated that the US Supreme Court declined to hear an appeal by generics on Lilly's Zyprexa:

Zenith Goldline Pharmaceuticals, Dr. Reddy's Laboratories and Teva Pharmaceutical Industries had argued that Lilly's patent was no longer valid because discovery of Zyprexa's molecular structure was covered by a previous Lilly patent.


Several states are suing Lilly, claiming it marketed Zyprexa for off-label uses, including treatment of dementia, depression and autism, without warning about its risks.



Post a Comment

<< Home